Sweden’s RhoVac Aims To Become An M&A Target
Late 2021 RV001 Phase IIb Data May Offer Trigger, CEO Says
RhoVac is in mid-stage trialing of a vaccine based on the RhoC protein that aids the metastatic potential of cancer cells and their ability to migrate and infiltrate other tissue. The Swedish biotech’s CEO believes the drug is a potential blockbuster.
